Vertex articles
-
Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 billion
With the acquisition, Vertex will add Alpine's portfolio of protein-based immunotherapies to treat autoimmune and inflammatory diseases.
-
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers
Patients suffering from pain have limited options when it comes to medication
-
Emfo LLC Sells 120 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Emfo LLC decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 47.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 134 shares of the pharmaceutical company’s stock after selling 120 shares during the period. Emfo LLC’s holdings in […]